Comments
Cadila Healthcare Ltd (Zydus Cadila) has received tentative approval from the USFDA for two anti-hypertensive drugs.
The approval has been given for Amlodipine Besylate and Benazepril Hydrochloride capsules in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg, the company said in a statement here on Saturday.
The estimated sales in 2012 according to IMS for Amlodipine Besylate and Benazepril Hydrochloride capsules was $384.8 million.
The group now has 78 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.